Related Experiment Videos
Cardiovascular effects of milrinone
1Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
American Heart Journal
|June 1, 1991
Summary
Milrinone, a phosphodiesterase III inhibitor, improves heart function by increasing cyclic adenosine monophosphate. This leads to enhanced contractility and vasodilation, proving beneficial for short-term heart failure management.
Area of Science:
- Cardiology
- Pharmacology
- Physiology
Background:
- Heart failure management requires agents that improve cardiac contractility and reduce vascular resistance.
- Phosphodiesterase III inhibitors represent a class of drugs with potential hemodynamic benefits.
Purpose of the Study:
- To elucidate the myocardial and vascular effects of milrinone.
- To compare the therapeutic profile of milrinone with other inotropic agents and vasodilators.
Main Methods:
- Direct coronary artery infusion of milrinone to assess immediate cardiac effects.
- Intravenous administration of milrinone to evaluate systemic hemodynamic responses.
- Analysis of left ventricular pressure-volume loops and myocardial relaxation parameters.
Main Results:
- Milrinone increased left ventricular contractility (+dP/dt) and stroke work, while reducing filling pressures.
- Systemic vascular resistance decreased, indicating significant vasodilation.
- Improved diastolic filling and accelerated isovolumic relaxation were observed, with unaltered myocardial oxygen demand.
Conclusions:
- Milrinone effectively improves cardiac pump function and hemodynamics through phosphodiesterase III inhibition.
- Its unique therapeutic profile distinguishes it from dobutamine and nitroprusside.
- Milrinone is a valuable option for the short-term management of heart failure patients.